Suppr超能文献

度拉糖肽引发的大疱性类天疱疮:一例病例报告及文献综述

Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature.

作者信息

Sonego Benedetta, Zelin Enrico, Zalaudek Iris, di Meo Nicola

机构信息

Dermatology Clinic of Trieste, Maggiore Hospital, University of Trieste, Italy.

出版信息

Dermatol Reports. 2023 Jun 6;15(3):9676. doi: 10.4081/dr.2023.9676. eCollection 2023 Sep 12.

Abstract

Bullous pemphigoid (BP) is an autoimmune disease with a chronic relapsing course, predominantly affecting elderly people. Drugs are one of the possible triggers. A class of antidiabetic drugs often associated with the development of BP are inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins), while less known is the association with glucagon-like-peptide-1 receptor agonists. We describe a case of BP caused by dulaglutide and summarize the other few cases described in the literature. As a class of drugs widely used in clinical practice, it is important to know about this possible adverse event.

摘要

大疱性类天疱疮(BP)是一种具有慢性复发病程的自身免疫性疾病,主要影响老年人。药物是可能的诱发因素之一。一类常与BP发生相关的抗糖尿病药物是二肽基肽酶4抑制剂(DPP-4抑制剂或格列汀类药物),而与胰高血糖素样肽-1受体激动剂的关联则鲜为人知。我们报告一例由度拉糖肽引起的BP病例,并总结文献中描述的其他少数病例。作为一类在临床实践中广泛使用的药物,了解这种可能的不良事件很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7cb5/10563024/2ea908f81450/dr-15-3-9676-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验